The application period will run from Aug. 4 – Nov. 21, 2025 at 1 p.m. EST.
The MLSC is running two programs designed to provide grants for capital projects that support the life sciences ecosystem in Massachusetts by enabling and supporting life sciences research and development in the Commonwealth. The two programs are the Research Infrastructure Program and the Research Equipment Program.
Research Infrastructure: Capital dollars are available to support capital projects ranging from $1.5 – $5 million to establish critical research resources across the state for not-for-profit organizations. Applicants will have to demonstrate how the requested infrastructure will benefit the entire life sciences ecosystem in Massachusetts.
Research Equipment: Capital dollars are available to support research equipment up to $500,000 across the state for not-for-profit organizations. Applicants will have to demonstrate how the requested piece(s) of equipment will benefit the entire life sciences ecosystem in Massachusetts.
Applicants must be a Massachusetts legally organized “not-for-profit” entity such as an academic/research institution, a hospital engaged in research, business incubator or accelerator, or other not-for-profit entity that would be eligible for capital funding from the Commonwealth of Massachusetts. Institutions that are exclusively health care providers and/or requests for the purchase of equipment associated with standard healthcare would not be eligible for capital funding.
Eligible applicants must meet the following criteria:
Massachusetts recognizes that investment in capital projects and infrastructure is required to create and sustain the attributes that make Massachusetts attractive to innovation clusters. To date, the MLSC has awarded or committed more than $615 million to support capital research infrastructure projects across the state.
Learn more about the 2020, 2021, 2022, 2023, and 2024 Research Infrastructure awardees.
Olaris is a precision diagnostics company that is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging their CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, they are able to harness the power of the body’s own communication system to discover and develop their pipeline of myOLARIS precision diagnostics.